Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nintedanib in Progressive Fibrotic Myositis Associated Interstitial Lung Disease
NCT05799755Phase 4Completed
- Start
- Aug 2023
- Primary completion
- Mar 2025
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 4 trial of nintedanib in myositis-associated interstitial lung disease (MA-ILD). Started Aug 2023; status: completed.
02
Drugs
nintedanib
03
Conditions
myositis-associated interstitial lung disease (MA-ILD)
Beyond the preview
Go deeper on NCT05799755.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05799755.